These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 21976529

  • 1. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.
    Haug AR, Rominger A, Mustafa M, Auernhammer C, Göke B, Schmidt GP, Wängler B, Cumming P, Bartenstein P, Hacker M.
    J Nucl Med; 2011 Nov; 52(11):1679-83. PubMed ID: 21976529
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [Abstract] [Full Text] [Related]

  • 3. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J.
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [Abstract] [Full Text] [Related]

  • 4. Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.
    Ayati N, Lee ST, Zakavi R, Pathmaraj K, Al-Qatawna L, Poon A, Scott AM.
    J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
    [Abstract] [Full Text] [Related]

  • 5. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, Almukhailed O, Kayani I, Syed R, Navalkissoor S, Ell PJ, Caplin ME, Bomanji J.
    J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
    Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, Cumming P, Bartenstein P, Tiling R, Hacker M.
    J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
    Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, Berthelsen AK, Langer SW, Rasmussen P, Elema D, von Benzon E, Højgaard L, Kjaer A.
    J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.
    Malmberg C, Ripa RS, Johnbeck CB, Knigge U, Langer SW, Mortensen J, Oturai P, Loft A, Hag AM, Kjær A.
    J Nucl Med; 2015 Dec; 56(12):1895-900. PubMed ID: 26429961
    [Abstract] [Full Text] [Related]

  • 19. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
    Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ.
    J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF, Sommer WH.
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.